The dihydroergotamine mesylate market is expected to grow at a significant CAGR during the forecast period (2021-2027). Dihydroergotamine is used to treat migraine headaches with or without aura, as well as cluster headache occurrences in the short term. Dihydroergotamine binds to 5-HT1Da and 5-HT1Db receptors with a high affinity. Serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, […]
